메뉴 건너뛰기




Volumn 85, Issue , 2015, Pages 83-99

Inhaled formulations and pulmonary drug delivery systems for respiratory infections

Author keywords

Dry powder inhaler; Inhaled antibiotics; Liposomes; Nanoparticles; Nebulisation; Particle engineering; Pharmaceutical aerosol; Polymeric particles

Indexed keywords

AEROSOLS; ANTIBIOTICS; CONTROLLED DRUG DELIVERY; DRUG DOSAGE; LIPOSOMES; NANOPARTICLES;

EID: 84930082717     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.10.022     Document Type: Review
Times cited : (208)

References (229)
  • 1
    • 84857621736 scopus 로고    scopus 로고
    • Inhaled colistin for lower respiratory tract infections
    • Antoniu S.A., Cojocaru I. Inhaled colistin for lower respiratory tract infections. Expert Opin. Drug Deliv. 2012, 9:333-342.
    • (2012) Expert Opin. Drug Deliv. , vol.9 , pp. 333-342
    • Antoniu, S.A.1    Cojocaru, I.2
  • 3
    • 70249104706 scopus 로고    scopus 로고
    • Delivery of antibiotics to the respiratory tract: an update
    • Traini D., Young P.M. Delivery of antibiotics to the respiratory tract: an update. Expert Opin. Drug Deliv. 2009, 6:897-905.
    • (2009) Expert Opin. Drug Deliv. , vol.6 , pp. 897-905
    • Traini, D.1    Young, P.M.2
  • 4
    • 84884254267 scopus 로고    scopus 로고
    • Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections
    • Yapa S.W.S., Li J., Porter C.J.H., Nation R.L., Patel K., McIntosh M.P. Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections. Antimicrob. Agents Chemother. 2013, 57:5087-5095.
    • (2013) Antimicrob. Agents Chemother. , vol.57 , pp. 5087-5095
    • Yapa, S.W.S.1    Li, J.2    Porter, C.J.H.3    Nation, R.L.4    Patel, K.5    McIntosh, M.P.6
  • 5
    • 79959248672 scopus 로고    scopus 로고
    • Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients
    • Garonzik S.M., Li J., Thamlikitkul V., Paterson D.L., Shoham S., Jacob J., Silveira F.P., Forrest A., Nation R.L. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 2011, 55:3284-3294.
    • (2011) Antimicrob. Agents Chemother. , vol.55 , pp. 3284-3294
    • Garonzik, S.M.1    Li, J.2    Thamlikitkul, V.3    Paterson, D.L.4    Shoham, S.5    Jacob, J.6    Silveira, F.P.7    Forrest, A.8    Nation, R.L.9
  • 6
    • 84875215401 scopus 로고    scopus 로고
    • Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study
    • Schuster A., Haliburn C., Döring G., Goldman M.H., Freedom Study Group Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013, 68:344-350.
    • (2013) Thorax , vol.68 , pp. 344-350
    • Schuster, A.1    Haliburn, C.2    Döring, G.3    Goldman, M.H.4
  • 9
    • 84930085610 scopus 로고    scopus 로고
    • Inhaled antimicrobial chemotherapy for respiratory tract infections: successes, challenges and the road ahead
    • Velkov T., Nusaibah A.R., Zhou Q., Chan H.-K., Li J. Inhaled antimicrobial chemotherapy for respiratory tract infections: successes, challenges and the road ahead. Adv. Drug Deliv. Rev. 2014.
    • (2014) Adv. Drug Deliv. Rev.
    • Velkov, T.1    Nusaibah, A.R.2    Zhou, Q.3    Chan, H.-K.4    Li, J.5
  • 10
    • 84890469602 scopus 로고    scopus 로고
    • Inhaled antibiotics to treat lung infection
    • Cipolla D., Chan H.-K. Inhaled antibiotics to treat lung infection. Pharm. Patent Anal. 2013, 2:647-663.
    • (2013) Pharm. Patent Anal. , vol.2 , pp. 647-663
    • Cipolla, D.1    Chan, H.-K.2
  • 11
    • 70349096824 scopus 로고    scopus 로고
    • Emerging treatments in cystic fibrosis
    • Jones A.M., Helm J.M. Emerging treatments in cystic fibrosis. Drugs 2009, 69:1903-1910.
    • (2009) Drugs , vol.69 , pp. 1903-1910
    • Jones, A.M.1    Helm, J.M.2
  • 12
    • 79953262396 scopus 로고    scopus 로고
    • Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis
    • Hoiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 2011, 9.
    • (2011) BMC Med. , vol.9
    • Hoiby, N.1
  • 13
    • 84902343133 scopus 로고    scopus 로고
    • Delivery of inhalation drugs to children for asthma and other respiratory diseases
    • Kwok P.C.L., Chan H.-K. Delivery of inhalation drugs to children for asthma and other respiratory diseases. Adv. Drug Deliv. Rev. 2014, 73:83-88.
    • (2014) Adv. Drug Deliv. Rev. , vol.73 , pp. 83-88
    • Kwok, P.C.L.1    Chan, H.-K.2
  • 14
    • 1242351697 scopus 로고    scopus 로고
    • Comparison of lung deposition in two types of nebulization - intrapulmonary percussive ventilation vs jet nebulization
    • Reychler G., Keyeux A., Cremers C., Veriter C., Rodenstein D.O., Liistro G. Comparison of lung deposition in two types of nebulization - intrapulmonary percussive ventilation vs jet nebulization. Chest 2004, 125:502-508.
    • (2004) Chest , vol.125 , pp. 502-508
    • Reychler, G.1    Keyeux, A.2    Cremers, C.3    Veriter, C.4    Rodenstein, D.O.5    Liistro, G.6
  • 15
    • 69549124208 scopus 로고    scopus 로고
    • Miniature inhalation therapy platform using surface acoustic wave microfluidic atomization
    • Qi A.S., Friend J.R., Yeo L.Y., Morton D.A.V., McIntosh M.P., Spiccia L. Miniature inhalation therapy platform using surface acoustic wave microfluidic atomization. Lab Chip 2009, 9:2184-2193.
    • (2009) Lab Chip , vol.9 , pp. 2184-2193
    • Qi, A.S.1    Friend, J.R.2    Yeo, L.Y.3    Morton, D.A.V.4    McIntosh, M.P.5    Spiccia, L.6
  • 17
    • 77950620340 scopus 로고    scopus 로고
    • Mode of breathing-tidal or slow and deep-through the I-neb adaptive aerosol delivery (AAD) system affects lung deposition of (99m) Tc-DTPA
    • Nikander K., Prince I., Coughlin S., Warren S., Taylor G. Mode of breathing-tidal or slow and deep-through the I-neb adaptive aerosol delivery (AAD) system affects lung deposition of (99m) Tc-DTPA. J. Aerosol Med. Pulm. Drug Deliv. 2010, 23(Suppl. 1):S37-S43.
    • (2010) J. Aerosol Med. Pulm. Drug Deliv. , vol.23 , pp. S37-S43
    • Nikander, K.1    Prince, I.2    Coughlin, S.3    Warren, S.4    Taylor, G.5
  • 18
    • 79954515565 scopus 로고    scopus 로고
    • Personalizing aerosol medicine: development of delivery systems tailored to the individual
    • Cipolla D., Chan H.K., Schuster J., Farina D. Personalizing aerosol medicine: development of delivery systems tailored to the individual. Ther. Deliv. 2010, 1:667-682.
    • (2010) Ther. Deliv. , vol.1 , pp. 667-682
    • Cipolla, D.1    Chan, H.K.2    Schuster, J.3    Farina, D.4
  • 19
    • 34247193128 scopus 로고    scopus 로고
    • Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety
    • Geller D.E., Konstan M.W., Noonberg S.B., Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr. Pulmonol. 2007, 42:307-313.
    • (2007) Pediatr. Pulmonol. , vol.42 , pp. 307-313
    • Geller, D.E.1    Konstan, M.W.2    Noonberg, S.B.3    Conrad, C.4
  • 23
    • 20144379949 scopus 로고    scopus 로고
    • Bacterial contamination of spacer devices used by asthmatic children
    • Cohen H.A., Cohen Z., Pomeranz A.S., Czitron B., Kahan E. Bacterial contamination of spacer devices used by asthmatic children. J. Asthma 2005, 42:169-172.
    • (2005) J. Asthma , vol.42 , pp. 169-172
    • Cohen, H.A.1    Cohen, Z.2    Pomeranz, A.S.3    Czitron, B.4    Kahan, E.5
  • 24
    • 12244290577 scopus 로고    scopus 로고
    • Bacterial contamination of inhalation chambers: results of a pilot study
    • De Vries T.W., Rienstra S.R., Van Der Vorm E.R. Bacterial contamination of inhalation chambers: results of a pilot study. J. Aerosol Med. 2004, 17:354-356.
    • (2004) J. Aerosol Med. , vol.17 , pp. 354-356
    • De Vries, T.W.1    Rienstra, S.R.2    Van Der Vorm, E.R.3
  • 25
    • 84858618162 scopus 로고    scopus 로고
    • Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces
    • Zhou Q., Morton D. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces. Adv. Drug Deliv. Rev. 2012, 64:275-284.
    • (2012) Adv. Drug Deliv. Rev. , vol.64 , pp. 275-284
    • Zhou, Q.1    Morton, D.2
  • 27
    • 84873706384 scopus 로고    scopus 로고
    • The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules
    • Sou T., Kaminskas L.M., Nguyen T.H., Carlberg R., McIntosh M.P., Morton D.A.V. The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules. Eur. J. Pharm. Biopharm. 2013, 83:234-243.
    • (2013) Eur. J. Pharm. Biopharm. , vol.83 , pp. 234-243
    • Sou, T.1    Kaminskas, L.M.2    Nguyen, T.H.3    Carlberg, R.4    McIntosh, M.P.5    Morton, D.A.V.6
  • 28
    • 81755166194 scopus 로고    scopus 로고
    • Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: a design of experiment approach
    • Sou T., Orlando L., McIntosh M.P., Kaminskas L.M., Morton D.A.V. Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: a design of experiment approach. Int. J. Pharm. 2011, 421:220-229.
    • (2011) Int. J. Pharm. , vol.421 , pp. 220-229
    • Sou, T.1    Orlando, L.2    McIntosh, M.P.3    Kaminskas, L.M.4    Morton, D.A.V.5
  • 29
    • 84896704931 scopus 로고    scopus 로고
    • Use of a fundamental approach to spray-drying formulation design to facilitate the development of multi-component dry powder aerosols for respiratory drug delivery
    • Hoe S., Ivey J.W., Boraey M.A., Shamsaddini-Shahrbabak A., Javaheri E., Matinkhoo S., Finlay W.H., Vehring R. Use of a fundamental approach to spray-drying formulation design to facilitate the development of multi-component dry powder aerosols for respiratory drug delivery. Pharm. Res. 2014, 31:449-465.
    • (2014) Pharm. Res. , vol.31 , pp. 449-465
    • Hoe, S.1    Ivey, J.W.2    Boraey, M.A.3    Shamsaddini-Shahrbabak, A.4    Javaheri, E.5    Matinkhoo, S.6    Finlay, W.H.7    Vehring, R.8
  • 30
    • 61849181513 scopus 로고    scopus 로고
    • Direct evidence on reduced adhesion of Salbutamol sulphate particles due to L-leucine coating
    • Paajanen M., Katainen J., Raula J., Kauppinen E.I., Lahtinen J. Direct evidence on reduced adhesion of Salbutamol sulphate particles due to L-leucine coating. Powder Technol. 2009, 192:6-11.
    • (2009) Powder Technol. , vol.192 , pp. 6-11
    • Paajanen, M.1    Katainen, J.2    Raula, J.3    Kauppinen, E.I.4    Lahtinen, J.5
  • 31
    • 72449183575 scopus 로고    scopus 로고
    • Investigations on particle surface characteristics vs. dispersion behaviour of L-leucine coated carrier-free inhalable powders
    • Raula J., Thielmann F., Naderi M., Lehto V.P., Kauppinen E.I. Investigations on particle surface characteristics vs. dispersion behaviour of L-leucine coated carrier-free inhalable powders. Int. J. Pharm. 2010, 385:79-85.
    • (2010) Int. J. Pharm. , vol.385 , pp. 79-85
    • Raula, J.1    Thielmann, F.2    Naderi, M.3    Lehto, V.P.4    Kauppinen, E.I.5
  • 32
    • 79961039597 scopus 로고    scopus 로고
    • Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere (TM) technology
    • Geller D.E., Weers J., Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere (TM) technology. J. Aerosol Med. Pulm. Drug Deliv. 2011, 24:175-182.
    • (2011) J. Aerosol Med. Pulm. Drug Deliv. , vol.24 , pp. 175-182
    • Geller, D.E.1    Weers, J.2    Heuerding, S.3
  • 34
    • 84896795789 scopus 로고    scopus 로고
    • The PulmoSphere™ platform for pulmonary drug delivery
    • Weers J., Tarara T. The PulmoSphere™ platform for pulmonary drug delivery. Ther. Deliv. 2014, 5:277-295.
    • (2014) Ther. Deliv. , vol.5 , pp. 277-295
    • Weers, J.1    Tarara, T.2
  • 38
    • 84877855898 scopus 로고    scopus 로고
    • Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis
    • Dharmadhikari A.S., Kabadi M., Gerety B., Hickey A.J., Fourie P.B., Nardell E. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis. Antimicrob. Agents Chemother. 2013, 57:2613-2619.
    • (2013) Antimicrob. Agents Chemother. , vol.57 , pp. 2613-2619
    • Dharmadhikari, A.S.1    Kabadi, M.2    Gerety, B.3    Hickey, A.J.4    Fourie, P.B.5    Nardell, E.6
  • 40
    • 84864645030 scopus 로고    scopus 로고
    • Preparation and characterisation of novel spray-dried nano-structured para-aminosalicylic acid particulates for pulmonary delivery: impact of ammonium carbonate on morphology, chemical composition and solid state
    • Gad S., Tajber L., Corrigan O.I., Healy A.M. Preparation and characterisation of novel spray-dried nano-structured para-aminosalicylic acid particulates for pulmonary delivery: impact of ammonium carbonate on morphology, chemical composition and solid state. J. Pharm. Pharmacol. 2012, 64:1264-1274.
    • (2012) J. Pharm. Pharmacol. , vol.64 , pp. 1264-1274
    • Gad, S.1    Tajber, L.2    Corrigan, O.I.3    Healy, A.M.4
  • 43
    • 77953812120 scopus 로고    scopus 로고
    • Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach
    • Zhou Q.T., Qu L., Larson I., Stewart P.J., Morton D.A.V. Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach. Int. J. Pharm. 2010, 394:50-59.
    • (2010) Int. J. Pharm. , vol.394 , pp. 50-59
    • Zhou, Q.T.1    Qu, L.2    Larson, I.3    Stewart, P.J.4    Morton, D.A.V.5
  • 44
    • 84878600984 scopus 로고    scopus 로고
    • Effect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers
    • Zhou Q., Qu L., Gengenbach T., Larson I., Stewart P.J., Morton D.A.V. Effect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers. AAPS Pharmscitech 2013, 14:38-44.
    • (2013) AAPS Pharmscitech , vol.14 , pp. 38-44
    • Zhou, Q.1    Qu, L.2    Gengenbach, T.3    Larson, I.4    Stewart, P.J.5    Morton, D.A.V.6
  • 45
    • 79958804877 scopus 로고    scopus 로고
    • Characterization of the surface properties of a model pharmaceutical fine powder modified with a pharmaceutical lubricant to improve flow via a mechanical dry coating approach
    • Zhou Q., Denman J.A., Gengenbach T., Das S., Qu L., Zhang H.L., Larson I., Stewart P.J., Morton D.A.V. Characterization of the surface properties of a model pharmaceutical fine powder modified with a pharmaceutical lubricant to improve flow via a mechanical dry coating approach. J. Pharm. Sci. 2011, 100:3421-3430.
    • (2011) J. Pharm. Sci. , vol.100 , pp. 3421-3430
    • Zhou, Q.1    Denman, J.A.2    Gengenbach, T.3    Das, S.4    Qu, L.5    Zhang, H.L.6    Larson, I.7    Stewart, P.J.8    Morton, D.A.V.9
  • 46
    • 77953957709 scopus 로고    scopus 로고
    • Understanding the influence of powder flowability, fluidization and de-agglomeration characteristics on the aerosolization of pharmaceutical model powders
    • Zhou Q.T., Armstrong B., Larson I., Stewart P.J., Morton D. Understanding the influence of powder flowability, fluidization and de-agglomeration characteristics on the aerosolization of pharmaceutical model powders. Eur. J. Pharm. Sci. 2010, 40:412-421.
    • (2010) Eur. J. Pharm. Sci. , vol.40 , pp. 412-421
    • Zhou, Q.T.1    Armstrong, B.2    Larson, I.3    Stewart, P.J.4    Morton, D.5
  • 47
    • 63949086375 scopus 로고    scopus 로고
    • Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency
    • Parlati C., Colombo P., Buttini F., Young P.M., Adi H., Ammit A.J., Traini D. Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency. Pharm. Res. 2009, 26:1084-1092.
    • (2009) Pharm. Res. , vol.26 , pp. 1084-1092
    • Parlati, C.1    Colombo, P.2    Buttini, F.3    Young, P.M.4    Adi, H.5    Ammit, A.J.6    Traini, D.7
  • 49
    • 84930088821 scopus 로고    scopus 로고
    • Inhaled antimicrobial therapy - barriers to effective treatment
    • Weers J. Inhaled antimicrobial therapy - barriers to effective treatment. Adv. Drug Deliv. Rev. 2014, (In press). 10.1016/j.addr.2014.08.013.
    • (2014) Adv. Drug Deliv. Rev.
    • Weers, J.1
  • 50
    • 0037177484 scopus 로고    scopus 로고
    • A study of the crystallisation of amorphous salbutamol sulphate using water vapour sorption and near infrared spectroscopy
    • Columbano A., Buckton G., Wikeley P. A study of the crystallisation of amorphous salbutamol sulphate using water vapour sorption and near infrared spectroscopy. Int. J. Pharm. 2002, 237:171-178.
    • (2002) Int. J. Pharm. , vol.237 , pp. 171-178
    • Columbano, A.1    Buckton, G.2    Wikeley, P.3
  • 51
    • 79958852605 scopus 로고    scopus 로고
    • Characterization and quantification of amorphous material in milled and spray-dried salbutamol sulfate: a comparison of thermal, spectroscopic, and water vapor sorption approaches
    • Grisedale L.C., Jamieson M.J., Belton P.S., Barker S.A., Craig D.Q.M. Characterization and quantification of amorphous material in milled and spray-dried salbutamol sulfate: a comparison of thermal, spectroscopic, and water vapor sorption approaches. J. Pharm. Sci. 2011, 100:3114-3129.
    • (2011) J. Pharm. Sci. , vol.100 , pp. 3114-3129
    • Grisedale, L.C.1    Jamieson, M.J.2    Belton, P.S.3    Barker, S.A.4    Craig, D.Q.M.5
  • 52
    • 84858798826 scopus 로고    scopus 로고
    • Isothermal microcalorimetry for quantifying amorphous content in processed pharmaceuticals
    • Gaisford S. Isothermal microcalorimetry for quantifying amorphous content in processed pharmaceuticals. Adv. Drug Deliv. Rev. 2012, 64:431-439.
    • (2012) Adv. Drug Deliv. Rev. , vol.64 , pp. 431-439
    • Gaisford, S.1
  • 53
    • 77953021975 scopus 로고    scopus 로고
    • Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease
    • Adi H., Young P.M., Chan H.-K., Agus H., Traini D. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur. J. Pharm. Sci. 2010, 40:239-247.
    • (2010) Eur. J. Pharm. Sci. , vol.40 , pp. 239-247
    • Adi, H.1    Young, P.M.2    Chan, H.-K.3    Agus, H.4    Traini, D.5
  • 54
    • 84883824014 scopus 로고    scopus 로고
    • Colistin powders with high aerosolisation efficiency for respiratory infection: preparation and in vitro evaluation
    • Zhou Q., Morton D., Yu H.H., Jacob J., Wang J.P., Li J., Chan H.K. Colistin powders with high aerosolisation efficiency for respiratory infection: preparation and in vitro evaluation. J. Pharm. Sci. 2013, 102:3736-3747.
    • (2013) J. Pharm. Sci. , vol.102 , pp. 3736-3747
    • Zhou, Q.1    Morton, D.2    Yu, H.H.3    Jacob, J.4    Wang, J.P.5    Li, J.6    Chan, H.K.7
  • 56
    • 84893113797 scopus 로고    scopus 로고
    • Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection
    • Zhou Q., Gengenbach T., Denman J., Yu H., Li J., Chan H. Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection. AAPS J. 2014, 16:37-47.
    • (2014) AAPS J. , vol.16 , pp. 37-47
    • Zhou, Q.1    Gengenbach, T.2    Denman, J.3    Yu, H.4    Li, J.5    Chan, H.6
  • 57
    • 33847797216 scopus 로고    scopus 로고
    • Liposome-based drug delivery to alveolar macrophages
    • Vyas S.P., Khatri K. Liposome-based drug delivery to alveolar macrophages. Expert Opin. Drug Deliv. 2007, 4:95-99.
    • (2007) Expert Opin. Drug Deliv. , vol.4 , pp. 95-99
    • Vyas, S.P.1    Khatri, K.2
  • 58
    • 80051496632 scopus 로고    scopus 로고
    • Targeted liposomal drug delivery to monocytes and macrophages
    • 727241
    • Kelly C., Jefferies C., Cryan S.-A. Targeted liposomal drug delivery to monocytes and macrophages. J. Drug Deliv. 2011, 727241.
    • (2011) J. Drug Deliv.
    • Kelly, C.1    Jefferies, C.2    Cryan, S.-A.3
  • 59
    • 84930084085 scopus 로고    scopus 로고
    • Liposomal ciprofloxacin preparation is active against Mycobacterium avium subsp hominissuis and Mycobacterium abscessus in macrophages and in biofilm
    • A6677, San Diego
    • Blanchard J., Danelishvili L., Gonda I., Bermudez L. Liposomal ciprofloxacin preparation is active against Mycobacterium avium subsp hominissuis and Mycobacterium abscessus in macrophages and in biofilm. 2014 American Thoracic Society Conference 2014, A6677, San Diego.
    • (2014) 2014 American Thoracic Society Conference
    • Blanchard, J.1    Danelishvili, L.2    Gonda, I.3    Bermudez, L.4
  • 60
    • 74949118665 scopus 로고    scopus 로고
    • Effect of surface-mannose modification on aerosolized liposomal delivery to alveolar macrophages
    • Chono S., Kaneko K., Yamamoto E., Togami K., Morimoto K. Effect of surface-mannose modification on aerosolized liposomal delivery to alveolar macrophages. Drug Dev. Ind. Pharm. 2010, 36:102-107.
    • (2010) Drug Dev. Ind. Pharm. , vol.36 , pp. 102-107
    • Chono, S.1    Kaneko, K.2    Yamamoto, E.3    Togami, K.4    Morimoto, K.5
  • 61
    • 40649093018 scopus 로고    scopus 로고
    • Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections
    • Chono S., Tanino T., Seki T., Morimoto K. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J. Control. Release 2008, 127:50-58.
    • (2008) J. Control. Release , vol.127 , pp. 50-58
    • Chono, S.1    Tanino, T.2    Seki, T.3    Morimoto, K.4
  • 62
    • 84908226561 scopus 로고    scopus 로고
    • Lipid-based carriers for pulmonary products: preclinical development and case studies in humans
    • Cipolla D., Shekunov B., Blanchard J., Hickey A. Lipid-based carriers for pulmonary products: preclinical development and case studies in humans. Adv. Drug Deliv. Rev. 2014, 75:53-80.
    • (2014) Adv. Drug Deliv. Rev. , vol.75 , pp. 53-80
    • Cipolla, D.1    Shekunov, B.2    Blanchard, J.3    Hickey, A.4
  • 65
    • 70350753018 scopus 로고    scopus 로고
    • Triggered release of ciprofloxacin from nanostructured agglomerated vesicles
    • Bhavane R., Karathanasis E., Annapragada A.V. Triggered release of ciprofloxacin from nanostructured agglomerated vesicles. Int. J. Nanomedicine 2007, 2:407-418.
    • (2007) Int. J. Nanomedicine , vol.2 , pp. 407-418
    • Bhavane, R.1    Karathanasis, E.2    Annapragada, A.V.3
  • 66
  • 67
    • 84881556337 scopus 로고    scopus 로고
    • Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial
    • Serisier D.J., Bilton D., De Soyza A., Thompson P.J., Kolbe J., Greville H.W., Cipolla D., Bruinenberg P., Gonda I. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013, 68:812-817.
    • (2013) Thorax , vol.68 , pp. 812-817
    • Serisier, D.J.1    Bilton, D.2    De Soyza, A.3    Thompson, P.J.4    Kolbe, J.5    Greville, H.W.6    Cipolla, D.7    Bruinenberg, P.8    Gonda, I.9
  • 71
    • 84907879111 scopus 로고    scopus 로고
    • Aerosol performance and long-term stability of surfactant-associated liposomal ciprofloxacin formulations with modified encapsulation and release properties
    • Cipolla D., Wu H., Gonda I., Chan H.-K. Aerosol performance and long-term stability of surfactant-associated liposomal ciprofloxacin formulations with modified encapsulation and release properties. AAPS Pharmscitech 2014, 1-10.
    • (2014) AAPS Pharmscitech , pp. 1-10
    • Cipolla, D.1    Wu, H.2    Gonda, I.3    Chan, H.-K.4
  • 73
    • 0037038303 scopus 로고    scopus 로고
    • A facile method of delivery of liposomes by nebulization
    • Desai T.R., Hancock R.E.W., Finlay W.H. A facile method of delivery of liposomes by nebulization. J. Control. Release 2002, 84:69-78.
    • (2002) J. Control. Release , vol.84 , pp. 69-78
    • Desai, T.R.1    Hancock, R.E.W.2    Finlay, W.H.3
  • 74
    • 0036167306 scopus 로고    scopus 로고
    • A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleterious effects of milling
    • Desai T.R., Wong J.P., Hancock R.E., Finlay W.H. A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleterious effects of milling. J. Pharm. Sci. 2002, 91:482-491.
    • (2002) J. Pharm. Sci. , vol.91 , pp. 482-491
    • Desai, T.R.1    Wong, J.P.2    Hancock, R.E.3    Finlay, W.H.4
  • 75
    • 0344083495 scopus 로고    scopus 로고
    • Delivery of liposomes in dry powder form: aerodynamic dispersion properties
    • Desai T.R., Hancock R.E.W., Finlay W.H. Delivery of liposomes in dry powder form: aerodynamic dispersion properties. Eur. J. Pharm. Sci. 2003, 20:459-467.
    • (2003) Eur. J. Pharm. Sci. , vol.20 , pp. 459-467
    • Desai, T.R.1    Hancock, R.E.W.2    Finlay, W.H.3
  • 77
    • 84886627480 scopus 로고    scopus 로고
    • Liposomal antibiotics for the treatment of infectious diseases
    • Alhariri M., Azghani A., Omri A. Liposomal antibiotics for the treatment of infectious diseases. Expert Opin. Drug Deliv. 2013, 10:1515-1532.
    • (2013) Expert Opin. Drug Deliv. , vol.10 , pp. 1515-1532
    • Alhariri, M.1    Azghani, A.2    Omri, A.3
  • 78
    • 34248199805 scopus 로고    scopus 로고
    • In vitro antimicrobial activity of liposomes containing ciprofloxacin, meropenem and gentamicin against gram-negative clinical bacterial strains
    • Gubernator J., Druis-Kawa Z., Dorotkiewicz-Jach A., Doroszkiewicz W., Kozubek A. In vitro antimicrobial activity of liposomes containing ciprofloxacin, meropenem and gentamicin against gram-negative clinical bacterial strains. Lett. Drug Des. Discov. 2007, 4:297-304.
    • (2007) Lett. Drug Des. Discov. , vol.4 , pp. 297-304
    • Gubernator, J.1    Druis-Kawa, Z.2    Dorotkiewicz-Jach, A.3    Doroszkiewicz, W.4    Kozubek, A.5
  • 79
    • 58249102178 scopus 로고    scopus 로고
    • The interaction between Pseudomonas aeruginosa cells and cationic PC:Chol:DOTAP liposomal vesicles versus outer-membrane structure and envelope properties of bacterial cell
    • Drulis-Kawa Z., Dorotkiewicz-Jach A., Gubernator J., Gula G., Bocer T., Doroszkiewicz W. The interaction between Pseudomonas aeruginosa cells and cationic PC:Chol:DOTAP liposomal vesicles versus outer-membrane structure and envelope properties of bacterial cell. Int. J. Pharm. 2009, 367:211-219.
    • (2009) Int. J. Pharm. , vol.367 , pp. 211-219
    • Drulis-Kawa, Z.1    Dorotkiewicz-Jach, A.2    Gubernator, J.3    Gula, G.4    Bocer, T.5    Doroszkiewicz, W.6
  • 80
    • 12244279936 scopus 로고    scopus 로고
    • In vitro evaluation of nebulization properties, antimicrobial activity, and regional airway surface liquid concentration of liposomal polymyxin B sulfate
    • Desai T., Tyrrell G., Ng T., Finlay W. In vitro evaluation of nebulization properties, antimicrobial activity, and regional airway surface liquid concentration of liposomal polymyxin B sulfate. Pharm. Res. 2003, 20:442-447.
    • (2003) Pharm. Res. , vol.20 , pp. 442-447
    • Desai, T.1    Tyrrell, G.2    Ng, T.3    Finlay, W.4
  • 81
    • 84878293341 scopus 로고    scopus 로고
    • Pharmacology of polymyxins: new insights into an 'old' class of antibiotics
    • Velkov T., Roberts K.D., Nation R.L., Thompson P.E., Li J. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics. Future Microbiol 2013, 8:711-724.
    • (2013) Future Microbiol , vol.8 , pp. 711-724
    • Velkov, T.1    Roberts, K.D.2    Nation, R.L.3    Thompson, P.E.4    Li, J.5
  • 82
    • 84864039471 scopus 로고    scopus 로고
    • Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation
    • Wallace S.J., Li J., Nation R.L., Prankerd R.J., Boyd B.J. Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation. J. Pharm. Sci. 2012, 101:3347-3359.
    • (2012) J. Pharm. Sci. , vol.101 , pp. 3347-3359
    • Wallace, S.J.1    Li, J.2    Nation, R.L.3    Prankerd, R.J.4    Boyd, B.J.5
  • 83
    • 68349105760 scopus 로고    scopus 로고
    • Polymyxin E sulfate-loaded liposome for intravenous use: preparation, lyophilization, and toxicity assessment in vivo
    • Wang D., Kong L., Wang J., He X., Li X., Xiao Y. Polymyxin E sulfate-loaded liposome for intravenous use: preparation, lyophilization, and toxicity assessment in vivo. PDA J. Pharm. Sci. Technol. 2009, 63:159-167.
    • (2009) PDA J. Pharm. Sci. Technol. , vol.63 , pp. 159-167
    • Wang, D.1    Kong, L.2    Wang, J.3    He, X.4    Li, X.5    Xiao, Y.6
  • 84
    • 84876325172 scopus 로고    scopus 로고
    • Physicochemical aspects of the coformulation of colistin and azithromycin using liposomes for combination antibiotic therapies
    • Wallace S.J., Nation R.L., Li J., Boyd B. Physicochemical aspects of the coformulation of colistin and azithromycin using liposomes for combination antibiotic therapies. J. Pharm. Sci. 2013, 102:1578-1587.
    • (2013) J. Pharm. Sci. , vol.102 , pp. 1578-1587
    • Wallace, S.J.1    Nation, R.L.2    Li, J.3    Boyd, B.4
  • 85
    • 24044532596 scopus 로고    scopus 로고
    • Delivery of liposomes generated from proliposomes using air-jet, ultrasonic, and vibrating-mesh nebulisers
    • Elhissi A.M.A., Taylor K.M.G. Delivery of liposomes generated from proliposomes using air-jet, ultrasonic, and vibrating-mesh nebulisers. J. Drug Deliv. Sci. Technol. 2005, 15:261-265.
    • (2005) J. Drug Deliv. Sci. Technol. , vol.15 , pp. 261-265
    • Elhissi, A.M.A.1    Taylor, K.M.G.2
  • 86
    • 0037038305 scopus 로고    scopus 로고
    • Preparation and evaluation of proliposomes containing salmon calcitonin
    • Song K.-H., Chung S.-J., Shim C.-K. Preparation and evaluation of proliposomes containing salmon calcitonin. J. Control. Release 2002, 84:27-37.
    • (2002) J. Control. Release , vol.84 , pp. 27-37
    • Song, K.-H.1    Chung, S.-J.2    Shim, C.-K.3
  • 87
    • 79960774579 scopus 로고    scopus 로고
    • Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies
    • Rojanarat W., Changsan N., Tawithong E., Pinsuwan S., Chan H.K., Srichana T. Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies. Int. J. Mol. Sci. 2011, 12:4414-4434.
    • (2011) Int. J. Mol. Sci. , vol.12 , pp. 4414-4434
    • Rojanarat, W.1    Changsan, N.2    Tawithong, E.3    Pinsuwan, S.4    Chan, H.K.5    Srichana, T.6
  • 88
    • 84895925406 scopus 로고    scopus 로고
    • Single step spray drying method to develop proliposomes for inhalation: a systematic study based on quality by design approach
    • Patil-Gadhe A., Pokharkar V. Single step spray drying method to develop proliposomes for inhalation: a systematic study based on quality by design approach. Pulm. Pharmacol. Ther. 2014, 27:197-207.
    • (2014) Pulm. Pharmacol. Ther. , vol.27 , pp. 197-207
    • Patil-Gadhe, A.1    Pokharkar, V.2
  • 90
    • 84890527843 scopus 로고    scopus 로고
    • Development and characterization of an in vitro release assay for liposomal ciprofloxacin for inhalation
    • Cipolla D., Wu H., Eastman S., Redelmeier T., Gonda I., Chan H.-K. Development and characterization of an in vitro release assay for liposomal ciprofloxacin for inhalation. J. Pharm. Sci. 2014, 103:314-327.
    • (2014) J. Pharm. Sci. , vol.103 , pp. 314-327
    • Cipolla, D.1    Wu, H.2    Eastman, S.3    Redelmeier, T.4    Gonda, I.5    Chan, H.-K.6
  • 91
    • 84872118822 scopus 로고    scopus 로고
    • Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia
    • Ong H.X., Traini D., Cipolla D., Gonda I., Bebawy M., Agus H., Young P.M. Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia. Pharm. Res. 2012, 29:3335-3346.
    • (2012) Pharm. Res. , vol.29 , pp. 3335-3346
    • Ong, H.X.1    Traini, D.2    Cipolla, D.3    Gonda, I.4    Bebawy, M.5    Agus, H.6    Young, P.M.7
  • 92
    • 84881539706 scopus 로고    scopus 로고
    • Liposomal formulations for inhalation
    • Cipolla D., Gonda I., Chan H.K. Liposomal formulations for inhalation. Ther. Deliv. 2013, 4:1047-1072.
    • (2013) Ther. Deliv. , vol.4 , pp. 1047-1072
    • Cipolla, D.1    Gonda, I.2    Chan, H.K.3
  • 93
    • 68249124509 scopus 로고    scopus 로고
    • Preparation and evaluation of controlled release microparticles for respiratory protein therapy
    • Salama R.O., Traini D., Chan H.K., Sung A., Ammit A.J., Young P.M. Preparation and evaluation of controlled release microparticles for respiratory protein therapy. J. Pharm. Sci. 2009, 98:2709-2717.
    • (2009) J. Pharm. Sci. , vol.98 , pp. 2709-2717
    • Salama, R.O.1    Traini, D.2    Chan, H.K.3    Sung, A.4    Ammit, A.J.5    Young, P.M.6
  • 94
    • 84876092106 scopus 로고    scopus 로고
    • Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano- and microscale particles
    • Roberts R.A., Shen T., Allen I.C., Hasan W., DeSimone J.M., Ting J.P.Y. Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano- and microscale particles. PLoS One 2013, 8:e62115.
    • (2013) PLoS One , vol.8 , pp. e62115
    • Roberts, R.A.1    Shen, T.2    Allen, I.C.3    Hasan, W.4    DeSimone, J.M.5    Ting, J.P.Y.6
  • 96
    • 0023886553 scopus 로고
    • Long term histopathologic follow-up of bronchial arteries after therapeutic embolization with polyvinyl alcohol (Ivalon) in patients with cystic fibrosis
    • Tomashefski J.F., Cohen A.M., Doershuk C.F. Long term histopathologic follow-up of bronchial arteries after therapeutic embolization with polyvinyl alcohol (Ivalon) in patients with cystic fibrosis. Hum. Pathol. 1988, 19:555-561.
    • (1988) Hum. Pathol. , vol.19 , pp. 555-561
    • Tomashefski, J.F.1    Cohen, A.M.2    Doershuk, C.F.3
  • 98
    • 77955453531 scopus 로고    scopus 로고
    • Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells: the effect of antibiotic release profile
    • Cheow W.S., Chang M.W., Hadinoto K. Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells: the effect of antibiotic release profile. Pharm. Res. 2010, 27:1597-1609.
    • (2010) Pharm. Res. , vol.27 , pp. 1597-1609
    • Cheow, W.S.1    Chang, M.W.2    Hadinoto, K.3
  • 99
    • 80054082800 scopus 로고    scopus 로고
    • The roles of lipid in anti-biofilm efficacy of lipid-polymer hybrid nanoparticles encapsulating antibiotics
    • Cheow W.S., Chang M.W., Hadinoto K. The roles of lipid in anti-biofilm efficacy of lipid-polymer hybrid nanoparticles encapsulating antibiotics. Colloids Surf. A Physicochem. Eng. Asp. 2011, 389:158-165.
    • (2011) Colloids Surf. A Physicochem. Eng. Asp. , vol.389 , pp. 158-165
    • Cheow, W.S.1    Chang, M.W.2    Hadinoto, K.3
  • 100
    • 81255137213 scopus 로고    scopus 로고
    • Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers
    • Ungaro F., d'Angelo I., Coletta C., Bianca R.D.D., Sorrentino R., Perfetto B., Tufano M.A., Miro A., La Rotonda M.I., Quaglia F. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J. Control. Release 2012, 157:149-159.
    • (2012) J. Control. Release , vol.157 , pp. 149-159
    • Ungaro, F.1    d'Angelo, I.2    Coletta, C.3    Bianca, R.D.D.4    Sorrentino, R.5    Perfetto, B.6    Tufano, M.A.7    Miro, A.8    La Rotonda, M.I.9    Quaglia, F.10
  • 101
    • 84864697452 scopus 로고    scopus 로고
    • Preparation of sustained release rifampicin microparticles for inhalation
    • Son Y.-J., McConville J.T. Preparation of sustained release rifampicin microparticles for inhalation. J. Pharm. Pharmacol. 2012, 64:1291-1302.
    • (2012) J. Pharm. Pharmacol. , vol.64 , pp. 1291-1302
    • Son, Y.-J.1    McConville, J.T.2
  • 102
    • 70350324932 scopus 로고    scopus 로고
    • Preparation of rifampicin-loaded PLGA microspheres for lung delivery as aerosol by premix membrane homogenization
    • Doan T.V.P., Olivier J.C. Preparation of rifampicin-loaded PLGA microspheres for lung delivery as aerosol by premix membrane homogenization. Int. J. Pharm. 2009, 382:61-66.
    • (2009) Int. J. Pharm. , vol.382 , pp. 61-66
    • Doan, T.V.P.1    Olivier, J.C.2
  • 104
    • 79959750261 scopus 로고    scopus 로고
    • Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery
    • Doan T.V.P., Couet W., Olivier J.C. Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery. Int. J. Pharm. 2011, 414:112-117.
    • (2011) Int. J. Pharm. , vol.414 , pp. 112-117
    • Doan, T.V.P.1    Couet, W.2    Olivier, J.C.3
  • 105
    • 84865799323 scopus 로고    scopus 로고
    • Formulation and in vitro characterization of inhalable polyvinyl alcohol-free rifampicin-loaded PLGA microspheres prepared with sucrose palmitate as stabilizer: efficiency for ex vivo alveolar macrophage targeting
    • Diab R., Brillault J., Bardy A., Gontijo A.V.L., Olivier J.C. Formulation and in vitro characterization of inhalable polyvinyl alcohol-free rifampicin-loaded PLGA microspheres prepared with sucrose palmitate as stabilizer: efficiency for ex vivo alveolar macrophage targeting. Int. J. Pharm. 2012, 436:833-839.
    • (2012) Int. J. Pharm. , vol.436 , pp. 833-839
    • Diab, R.1    Brillault, J.2    Bardy, A.3    Gontijo, A.V.L.4    Olivier, J.C.5
  • 106
    • 34247639902 scopus 로고    scopus 로고
    • Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content
    • Budhian A., Siegel S.J., Winey K.I. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int. J. Pharm. 2007, 336:367-375.
    • (2007) Int. J. Pharm. , vol.336 , pp. 367-375
    • Budhian, A.1    Siegel, S.J.2    Winey, K.I.3
  • 107
    • 47249088124 scopus 로고    scopus 로고
    • Effect of polyethylene glycol on preparation of rifampicin-loaded PLGA microspheres with membrane emulsification technique
    • Ito F., Fujimori H., Honnami H., Kawakami H., Kanamura K., Makino K. Effect of polyethylene glycol on preparation of rifampicin-loaded PLGA microspheres with membrane emulsification technique. Colloids Surf. B: Biointerfaces 2008, 66:65-70.
    • (2008) Colloids Surf. B: Biointerfaces , vol.66 , pp. 65-70
    • Ito, F.1    Fujimori, H.2    Honnami, H.3    Kawakami, H.4    Kanamura, K.5    Makino, K.6
  • 108
    • 84860576610 scopus 로고    scopus 로고
    • Preparation and characterization of rifampicin-PLGA microspheres/sodium alginate in situ gel combination delivery system
    • Hu C., Feng H., Zhu C. Preparation and characterization of rifampicin-PLGA microspheres/sodium alginate in situ gel combination delivery system. Colloids Surf. B: Biointerfaces 2012, 95:162-169.
    • (2012) Colloids Surf. B: Biointerfaces , vol.95 , pp. 162-169
    • Hu, C.1    Feng, H.2    Zhu, C.3
  • 110
    • 80053415669 scopus 로고    scopus 로고
    • Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid
    • Pourshahab P.S., Gilani K., Moazeni E., Eslahi H., Fazeli M.R., Jamalifar H. Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid. J. Microencapsul. 2011, 28:605-613.
    • (2011) J. Microencapsul. , vol.28 , pp. 605-613
    • Pourshahab, P.S.1    Gilani, K.2    Moazeni, E.3    Eslahi, H.4    Fazeli, M.R.5    Jamalifar, H.6
  • 111
    • 79957692320 scopus 로고    scopus 로고
    • Formation, characterization, and fate of inhaled drug nanoparticles
    • Zhang J., Wu L., Chan H.-K., Watanabe W. Formation, characterization, and fate of inhaled drug nanoparticles. Adv. Drug Deliv. Rev. 2011, 63:441-455.
    • (2011) Adv. Drug Deliv. Rev. , vol.63 , pp. 441-455
    • Zhang, J.1    Wu, L.2    Chan, H.-K.3    Watanabe, W.4
  • 112
    • 84862776736 scopus 로고    scopus 로고
    • A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles
    • Wang Y.J., Kho K., Cheow W.S., Hadinoto K. A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles. Int. J. Pharm. 2012, 424:98-106.
    • (2012) Int. J. Pharm. , vol.424 , pp. 98-106
    • Wang, Y.J.1    Kho, K.2    Cheow, W.S.3    Hadinoto, K.4
  • 113
    • 80054697360 scopus 로고    scopus 로고
    • Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former
    • Yamasaki K., Kwok P.C.L., Fukushige K., Prud'homme R.K., Chan H.K. Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former. Int. J. Pharm. 2011, 420:34-42.
    • (2011) Int. J. Pharm. , vol.420 , pp. 34-42
    • Yamasaki, K.1    Kwok, P.C.L.2    Fukushige, K.3    Prud'homme, R.K.4    Chan, H.K.5
  • 115
    • 78650677959 scopus 로고    scopus 로고
    • Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants
    • Cheow W.S., Ng M.L.L., Kho K., Hadinoto K. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants. Int. J. Pharm. 2011, 404:289-300.
    • (2011) Int. J. Pharm. , vol.404 , pp. 289-300
    • Cheow, W.S.1    Ng, M.L.L.2    Kho, K.3    Hadinoto, K.4
  • 116
    • 84886099200 scopus 로고    scopus 로고
    • Aerosol delivery of nanoparticles in uniform mannitol carriers formulated by ultrasonic spray freeze drying
    • D'Addio S.M., Chan J.G.Y., Kwok P.C.L., Benson B.R., Prud'homme R.K., Chan H.-K. Aerosol delivery of nanoparticles in uniform mannitol carriers formulated by ultrasonic spray freeze drying. Pharm. Res. 2013, 30:2891-2901.
    • (2013) Pharm. Res. , vol.30 , pp. 2891-2901
    • D'Addio, S.M.1    Chan, J.G.Y.2    Kwok, P.C.L.3    Benson, B.R.4    Prud'homme, R.K.5    Chan, H.-K.6
  • 117
    • 84859106992 scopus 로고    scopus 로고
    • Constant size, variable density aerosol particles by ultrasonic spray freeze drying
    • D'Addio S.M., Chan J.G.Y., Kwok P.C.L., Prud'homme R.K., Chan H.-K. Constant size, variable density aerosol particles by ultrasonic spray freeze drying. Int. J. Pharm. 2012, 427:185-191.
    • (2012) Int. J. Pharm. , vol.427 , pp. 185-191
    • D'Addio, S.M.1    Chan, J.G.Y.2    Kwok, P.C.L.3    Prud'homme, R.K.4    Chan, H.-K.5
  • 118
  • 119
    • 84857423152 scopus 로고    scopus 로고
    • Optimization of freeze-drying condition of amikacin solid lipid nanoparticles using D-optimal experimental design
    • Varshosaz J., Ghaffari S., Khoshayand M.R., Atyabi F., Dehkordi A.J., Kobarfard F. Optimization of freeze-drying condition of amikacin solid lipid nanoparticles using D-optimal experimental design. Pharm. Dev. Technol. 2012, 17:187-194.
    • (2012) Pharm. Dev. Technol. , vol.17 , pp. 187-194
    • Varshosaz, J.1    Ghaffari, S.2    Khoshayand, M.R.3    Atyabi, F.4    Dehkordi, A.J.5    Kobarfard, F.6
  • 120
    • 79251488476 scopus 로고    scopus 로고
    • Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles
    • Ghaffari S., Varshosaz J., Saadat A., Atyabi F. Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles. Int. J. Nanomedicine 2010, 6:35-43.
    • (2010) Int. J. Nanomedicine , vol.6 , pp. 35-43
    • Ghaffari, S.1    Varshosaz, J.2    Saadat, A.3    Atyabi, F.4
  • 121
    • 77958098366 scopus 로고    scopus 로고
    • Agglomerates of ciprofloxacin nanoparticles yield fine dry powder aerosols
    • El-Gendy N., Desai V., Berkland C. Agglomerates of ciprofloxacin nanoparticles yield fine dry powder aerosols. J. Pharm. Innov. 2010, 5:79-87.
    • (2010) J. Pharm. Innov. , vol.5 , pp. 79-87
    • El-Gendy, N.1    Desai, V.2    Berkland, C.3
  • 122
    • 57049159889 scopus 로고    scopus 로고
    • Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery
    • Pilcer G., Vanderbist F., Amighi K. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery. Int. J. Pharm. 2009, 365:162-169.
    • (2009) Int. J. Pharm. , vol.365 , pp. 162-169
    • Pilcer, G.1    Vanderbist, F.2    Amighi, K.3
  • 124
    • 84864040393 scopus 로고    scopus 로고
    • Development of budesonide nanocluster dry powder aerosols: processing
    • El-Gendy N., Selvam P., Soni P., Berkland C. Development of budesonide nanocluster dry powder aerosols: processing. J. Pharm. Sci. 2012, 101:3425-3433.
    • (2012) J. Pharm. Sci. , vol.101 , pp. 3425-3433
    • El-Gendy, N.1    Selvam, P.2    Soni, P.3    Berkland, C.4
  • 125
    • 84899430751 scopus 로고    scopus 로고
    • Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product
    • Backman P., Adelmann H., Petersson G., Jones C.B. Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product. Clin. Pharmacol. Ther. 2014, 95:509-520.
    • (2014) Clin. Pharmacol. Ther. , vol.95 , pp. 509-520
    • Backman, P.1    Adelmann, H.2    Petersson, G.3    Jones, C.B.4
  • 130
    • 33645396484 scopus 로고    scopus 로고
    • Functional classification of drugs by properties of their pairwise interactions
    • Yeh P., Tschumi A.I., Kishony R. Functional classification of drugs by properties of their pairwise interactions. Nat. Genet. 2006, 38:489-494.
    • (2006) Nat. Genet. , vol.38 , pp. 489-494
    • Yeh, P.1    Tschumi, A.I.2    Kishony, R.3
  • 133
    • 67651218977 scopus 로고    scopus 로고
    • Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa
    • Tre-Hardy M., Traore H., El Manssouri N., Vanderbist F., Vaneechoutte M., Devleeschouwer M.J. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 2009, 34:370-374.
    • (2009) Int. J. Antimicrob. Agents , vol.34 , pp. 370-374
    • Tre-Hardy, M.1    Traore, H.2    El Manssouri, N.3    Vanderbist, F.4    Vaneechoutte, M.5    Devleeschouwer, M.J.6
  • 136
    • 84855255192 scopus 로고    scopus 로고
    • Fosfomycin/tobramycin for inhalation (FTI): microbiological results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and Pseudomonas aeruginosa
    • McColley S.A., Trapnell B., Kissner D., McKevitt M., Montgomery B., Rosen J. Fosfomycin/tobramycin for inhalation (FTI): microbiological results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and Pseudomonas aeruginosa. Pediatr. Pulmonol. 2010, 338-338.
    • (2010) Pediatr. Pulmonol. , pp. 338-338
    • McColley, S.A.1    Trapnell, B.2    Kissner, D.3    McKevitt, M.4    Montgomery, B.5    Rosen, J.6
  • 137
    • 84873722026 scopus 로고    scopus 로고
    • Synergistic combination dry powders for inhaled antimicrobial therapy: formulation, characterization and in vitro evaluation
    • Lee S.H., Teo J., Heng D., Ng W.K., Chan H.-K., Tan R.B.H. Synergistic combination dry powders for inhaled antimicrobial therapy: formulation, characterization and in vitro evaluation. Eur. J. Pharm. Biopharm. 2013, 83:275-284.
    • (2013) Eur. J. Pharm. Biopharm. , vol.83 , pp. 275-284
    • Lee, S.H.1    Teo, J.2    Heng, D.3    Ng, W.K.4    Chan, H.-K.5    Tan, R.B.H.6
  • 138
    • 75449151225 scopus 로고
    • Ineffectiveness of lysozyme therapy in experimental syphilis in the rabbit
    • Cannefax G.R., Hanson A.W. Ineffectiveness of lysozyme therapy in experimental syphilis in the rabbit. Br. J. Venereal Dis. 1963, 39:192-194.
    • (1963) Br. J. Venereal Dis. , vol.39 , pp. 192-194
    • Cannefax, G.R.1    Hanson, A.W.2
  • 140
    • 84878571643 scopus 로고    scopus 로고
    • Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis
    • Pilcer G., De Bueger V., Traina K., Traore H., Sebti T., Vanderbist F., Amighi K. Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis. Int. J. Pharm. 2013, 451:112-120.
    • (2013) Int. J. Pharm. , vol.451 , pp. 112-120
    • Pilcer, G.1    De Bueger, V.2    Traina, K.3    Traore, H.4    Sebti, T.5    Vanderbist, F.6    Amighi, K.7
  • 141
    • 84930088889 scopus 로고    scopus 로고
    • Formulation and evaluation of dry powders containing anti tuberculosis drugs for pulmonary delivery
    • Gowda D.V., Datta V., Meenakshi S., Gupta V.K. Formulation and evaluation of dry powders containing anti tuberculosis drugs for pulmonary delivery. Indo Am. J. Pharm. Res. 2013, 3:1239-1248.
    • (2013) Indo Am. J. Pharm. Res. , vol.3 , pp. 1239-1248
    • Gowda, D.V.1    Datta, V.2    Meenakshi, S.3    Gupta, V.K.4
  • 142
  • 145
    • 0034781469 scopus 로고    scopus 로고
    • Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis
    • Sharma R., Saxena D., Dwivedi A., Misra A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm. Res. 2001, 18:1405-1410.
    • (2001) Pharm. Res. , vol.18 , pp. 1405-1410
    • Sharma, R.1    Saxena, D.2    Dwivedi, A.3    Misra, A.4
  • 146
    • 0025888898 scopus 로고
    • Stability of isoniazid, rifampin and pyrazinamide in suspensions used for the treatment of tuberculosis in children
    • Seifart H.I., Parkin D.P., Donald P.R. Stability of isoniazid, rifampin and pyrazinamide in suspensions used for the treatment of tuberculosis in children. Pediatr. Infect. Dis. J. 1991, 10:827-831.
    • (1991) Pediatr. Infect. Dis. J. , vol.10 , pp. 827-831
    • Seifart, H.I.1    Parkin, D.P.2    Donald, P.R.3
  • 147
    • 49049116192 scopus 로고    scopus 로고
    • The role of chelators in preventing biofilm formation and catheter-related bloodstream infections
    • Raad I.I., Fang X., Keutgen X.M., Jiang Y., Sherertz R., Hachem R. The role of chelators in preventing biofilm formation and catheter-related bloodstream infections. Curr. Opin. Infect. Dis. 2008, 21:385-392.
    • (2008) Curr. Opin. Infect. Dis. , vol.21 , pp. 385-392
    • Raad, I.I.1    Fang, X.2    Keutgen, X.M.3    Jiang, Y.4    Sherertz, R.5    Hachem, R.6
  • 148
    • 84872731672 scopus 로고    scopus 로고
    • Antibiotic-EDTA combination induced dispersal of Pseudomonas aeruginosa biofilm
    • Shaikh A.I., Musaddiq M. Antibiotic-EDTA combination induced dispersal of Pseudomonas aeruginosa biofilm. J. Pure Appl. Microbiol. 2012, 6:363-367.
    • (2012) J. Pure Appl. Microbiol. , vol.6 , pp. 363-367
    • Shaikh, A.I.1    Musaddiq, M.2
  • 149
    • 0037198693 scopus 로고    scopus 로고
    • A component of innate immunity prevents bacterial biofilm development
    • Singh P.K., Parsek M.R., Greenberg E.P., Welsh M.J. A component of innate immunity prevents bacterial biofilm development. Nature 2002, 417:552-555.
    • (2002) Nature , vol.417 , pp. 552-555
    • Singh, P.K.1    Parsek, M.R.2    Greenberg, E.P.3    Welsh, M.J.4
  • 150
    • 79952953111 scopus 로고    scopus 로고
    • Mannitol-guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model
    • Yang Y., Tsifansky M.D., Shin S., Lin Q., Yeo Y. Mannitol-guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model. Biotechnol. Bioeng. 2011, 108:1441-1449.
    • (2011) Biotechnol. Bioeng. , vol.108 , pp. 1441-1449
    • Yang, Y.1    Tsifansky, M.D.2    Shin, S.3    Lin, Q.4    Yeo, Y.5
  • 152
    • 79955886933 scopus 로고    scopus 로고
    • Metabolite-enabled eradication of bacterial persisters by aminoglycosides
    • Allison K.R., Brynildsen M.P., Collins J.J. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 2011, 473:216-220.
    • (2011) Nature , vol.473 , pp. 216-220
    • Allison, K.R.1    Brynildsen, M.P.2    Collins, J.J.3
  • 153
    • 84892500332 scopus 로고    scopus 로고
    • Mannitol enhances antibiotic sensitivity of persister bacteria in Pseudomonas aeruginosa biofilms
    • Barraud N., Buson A., Jarolimek W., Rice S.A. Mannitol enhances antibiotic sensitivity of persister bacteria in Pseudomonas aeruginosa biofilms. PLoS One 2013, 8.
    • (2013) PLoS One , vol.8
    • Barraud, N.1    Buson, A.2    Jarolimek, W.3    Rice, S.A.4
  • 155
    • 84880078608 scopus 로고    scopus 로고
    • Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis
    • Bilton D., Daviskas E., Anderson S.D., Kolbe J., King G., Stirling R.G., Thompson B.R., Milne D., Charlton B., Investigators B. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013, 144:215-225.
    • (2013) Chest , vol.144 , pp. 215-225
    • Bilton, D.1    Daviskas, E.2    Anderson, S.D.3    Kolbe, J.4    King, G.5    Stirling, R.G.6    Thompson, B.R.7    Milne, D.8    Charlton, B.9    Investigators, B.10
  • 156
    • 72949104558 scopus 로고    scopus 로고
    • Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis
    • Yang Y., Tsifansky M.D., Wu C.J., Yang H.I., Schmidt G., Yeo Y. Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis. Pharm. Res. 2010, 27:151-160.
    • (2010) Pharm. Res. , vol.27 , pp. 151-160
    • Yang, Y.1    Tsifansky, M.D.2    Wu, C.J.3    Yang, H.I.4    Schmidt, G.5    Yeo, Y.6
  • 157
    • 84896360592 scopus 로고    scopus 로고
    • Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy
    • Lee S.H., Teo J., Heng D., Zhao Y., Ng W.K., Chan H.-K., Tan R.B.H. Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy. J. Pharm. Sci. 2014, 103:1115-1125.
    • (2014) J. Pharm. Sci. , vol.103 , pp. 1115-1125
    • Lee, S.H.1    Teo, J.2    Heng, D.3    Zhao, Y.4    Ng, W.K.5    Chan, H.-K.6    Tan, R.B.H.7
  • 159
    • 72249092095 scopus 로고    scopus 로고
    • Nitric oxide signaling in pseudomonas aeruginosa biofilms mediates phosphodiesterase activity, decreased cyclic Di-GMP levels, and enhanced dispersal
    • Barraud N., Schleheck D., Klebensberger J., Webb J.S., Hassett D.J., Rice S.A., Kjelleberg S. Nitric oxide signaling in pseudomonas aeruginosa biofilms mediates phosphodiesterase activity, decreased cyclic Di-GMP levels, and enhanced dispersal. J. Bacteriol. 2009, 191:7333-7342.
    • (2009) J. Bacteriol. , vol.191 , pp. 7333-7342
    • Barraud, N.1    Schleheck, D.2    Klebensberger, J.3    Webb, J.S.4    Hassett, D.J.5    Rice, S.A.6    Kjelleberg, S.7
  • 160
    • 72249093590 scopus 로고    scopus 로고
    • Nitric oxide-mediated dispersal in single- and multi-species biofilms of clinically and industrially relevant microorganisms
    • Barraud N., Storey M.V., Moore Z.P., Webb J.S., Rice S.A., Kjelleberg S. Nitric oxide-mediated dispersal in single- and multi-species biofilms of clinically and industrially relevant microorganisms. Microb. Biotechnol. 2009, 2:370-378.
    • (2009) Microb. Biotechnol. , vol.2 , pp. 370-378
    • Barraud, N.1    Storey, M.V.2    Moore, Z.P.3    Webb, J.S.4    Rice, S.A.5    Kjelleberg, S.6
  • 163
    • 60649119122 scopus 로고    scopus 로고
    • Preventing biofilms of clinically relevant organisms using bacteriophage
    • Donlan R.M. Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol. 2009, 17:66-72.
    • (2009) Trends Microbiol. , vol.17 , pp. 66-72
    • Donlan, R.M.1
  • 165
    • 34547448587 scopus 로고    scopus 로고
    • Dispersing biofilms with engineered enzymatic bacteriophage
    • Lu T.K., Collins J.J. Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11197-11202.
    • (2007) Proc. Natl. Acad. Sci. U. S. A. , vol.104 , pp. 11197-11202
    • Lu, T.K.1    Collins, J.J.2
  • 166
    • 84992305842 scopus 로고    scopus 로고
    • Formulation challenges: protein powders for inhalation
    • Informa Healthcare, New York, M. Rathbone, J. Hadgraft, M. Roberts (Eds.)
    • Chan H.-K. Formulation challenges: protein powders for inhalation. Modified-release Drug Delivery Technology 2008, 631-643. Informa Healthcare, New York. M. Rathbone, J. Hadgraft, M. Roberts (Eds.).
    • (2008) Modified-release Drug Delivery Technology , pp. 631-643
    • Chan, H.-K.1
  • 167
    • 0001848965 scopus 로고    scopus 로고
    • The balance between biochemical and physical stability for inhalation protein powders: rhDNase as an example
    • Interpharm Press, Buffalo Grove, IL, R. Dalby, P. Byron, S. Farr (Eds.)
    • Clark A., Dasovich N., Gonda I., Chan H.-K. The balance between biochemical and physical stability for inhalation protein powders: rhDNase as an example. Respiratory Drug Delivery V 1996, 167-174. Interpharm Press, Buffalo Grove, IL. R. Dalby, P. Byron, S. Farr (Eds.).
    • (1996) Respiratory Drug Delivery V , pp. 167-174
    • Clark, A.1    Dasovich, N.2    Gonda, I.3    Chan, H.-K.4
  • 168
    • 84882499572 scopus 로고    scopus 로고
    • Pulmonary delivery of peptides and proteins
    • Academic Press, London, C. Walle (Ed.)
    • Kwok P., Chan H.-K. Pulmonary delivery of peptides and proteins. Peptide and Protein Delivery 2011, 23-46. Academic Press, London. C. Walle (Ed.).
    • (2011) Peptide and Protein Delivery , pp. 23-46
    • Kwok, P.1    Chan, H.-K.2
  • 169
    • 84886146327 scopus 로고    scopus 로고
    • Proteins, peptides, and controlled-release formulations for inhalation
    • John Wiley & Sons, P. Colombo, D. Traini, F. Buttini (Eds.)
    • Kwok P., Salama R., Chan H.-K. Proteins, peptides, and controlled-release formulations for inhalation. Inhalation Drug Delivery: Techniques and Products 2012, 121-144. John Wiley & Sons. P. Colombo, D. Traini, F. Buttini (Eds.).
    • (2012) Inhalation Drug Delivery: Techniques and Products , pp. 121-144
    • Kwok, P.1    Salama, R.2    Chan, H.-K.3
  • 170
    • 0031008878 scopus 로고    scopus 로고
    • Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery
    • Chan H.K., Clark A., Gonda I., Mumenthaler M., Hsu C. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm. Res. 1997, 14:431-437.
    • (1997) Pharm. Res. , vol.14 , pp. 431-437
    • Chan, H.K.1    Clark, A.2    Gonda, I.3    Mumenthaler, M.4    Hsu, C.5
  • 171
    • 0031596775 scopus 로고    scopus 로고
    • Solid state characterization of spray-dried powders of recombinant human deoxyribonuclease (RhDNase)
    • Chan H.K., Gonda I. Solid state characterization of spray-dried powders of recombinant human deoxyribonuclease (RhDNase). J. Pharm. Sci. 1998, 87:647-654.
    • (1998) J. Pharm. Sci. , vol.87 , pp. 647-654
    • Chan, H.K.1    Gonda, I.2
  • 172
    • 0032425197 scopus 로고    scopus 로고
    • A solid-state NMR study of protein hydration and stability
    • Separovic F., Lam Y.H., Ke X., Chan H.K. A solid-state NMR study of protein hydration and stability. Pharm. Res. 1998, 15:1816-1821.
    • (1998) Pharm. Res. , vol.15 , pp. 1816-1821
    • Separovic, F.1    Lam, Y.H.2    Ke, X.3    Chan, H.K.4
  • 173
    • 0036279490 scopus 로고    scopus 로고
    • A solid-state NMR study of protein mobility in lyophilized protein-sugar powders
    • Lam Y.H., Bustami R., Phan T., Chan H.K., Separovic F. A solid-state NMR study of protein mobility in lyophilized protein-sugar powders. J. Pharm. Sci. 2002, 91:943-951.
    • (2002) J. Pharm. Sci. , vol.91 , pp. 943-951
    • Lam, Y.H.1    Bustami, R.2    Phan, T.3    Chan, H.K.4    Separovic, F.5
  • 174
    • 0012074293 scopus 로고
    • A case study in aerosol protein drug development: aqueous solution aerosols of rhDNase
    • Interpharm Press, Buffalo Grove, IL, P. Byron, R. Dalby, S. Farr (Eds.)
    • Gonda I., Cipolla D., Shire S., Meserve K., Weck S., Clark A., Chan H.-K. A case study in aerosol protein drug development: aqueous solution aerosols of rhDNase. Respiratory Drug Delivery IV 1994, 47-54. Interpharm Press, Buffalo Grove, IL. P. Byron, R. Dalby, S. Farr (Eds.).
    • (1994) Respiratory Drug Delivery IV , pp. 47-54
    • Gonda, I.1    Cipolla, D.2    Shire, S.3    Meserve, K.4    Weck, S.5    Clark, A.6    Chan, H.-K.7
  • 175
    • 0034495097 scopus 로고    scopus 로고
    • Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide
    • Bustami R.T., Chan H.K., Dehghani F., Foster N.R. Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide. Pharm. Res. 2000, 17:1360-1366.
    • (2000) Pharm. Res. , vol.17 , pp. 1360-1366
    • Bustami, R.T.1    Chan, H.K.2    Dehghani, F.3    Foster, N.R.4
  • 176
    • 0036367565 scopus 로고    scopus 로고
    • Aerosolization of protein solutions using thermal inkjet technology
    • Goodall S., Chew N., Chan K., Auriac D., Waters M.J. Aerosolization of protein solutions using thermal inkjet technology. J. Aerosol Med. 2002, 15:351-357.
    • (2002) J. Aerosol Med. , vol.15 , pp. 351-357
    • Goodall, S.1    Chew, N.2    Chan, K.3    Auriac, D.4    Waters, M.J.5
  • 177
    • 68249124509 scopus 로고    scopus 로고
    • Preparation and evaluation of controlled release microparticles for respiratory protein therapy
    • Salama R.O., Traini D., Chan H.K., Sung A., Ammit A.J., Young P.M. Preparation and evaluation of controlled release microparticles for respiratory protein therapy. J. Pharm. Sci. 2009, 98:2709-2717.
    • (2009) J. Pharm. Sci. , vol.98 , pp. 2709-2717
    • Salama, R.O.1    Traini, D.2    Chan, H.K.3    Sung, A.4    Ammit, A.J.5    Young, P.M.6
  • 178
    • 78650179651 scopus 로고    scopus 로고
    • Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy
    • Lee S.H., Heng D., Ng W.K., Chan H.K., Tan R.B.H. Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy. Int. J. Pharm. 2011, 403:192-200.
    • (2011) Int. J. Pharm. , vol.403 , pp. 192-200
    • Lee, S.H.1    Heng, D.2    Ng, W.K.3    Chan, H.K.4    Tan, R.B.H.5
  • 179
    • 79955603054 scopus 로고    scopus 로고
    • Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery
    • Kwok P.C.L., Tunsirikongkon A., Glover W., Chan H.K. Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery. Pharm. Res. 2011, 28:788-796.
    • (2011) Pharm. Res. , vol.28 , pp. 788-796
    • Kwok, P.C.L.1    Tunsirikongkon, A.2    Glover, W.3    Chan, H.K.4
  • 180
    • 84882896414 scopus 로고    scopus 로고
    • TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines
    • Tyne A.S., Chan J.G.Y., Shanahan E.R., Atmosukarto I., Chan H.-K., Britton W.J., West N.P. TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines. Vaccine 2013, 31:4322-4329.
    • (2013) Vaccine , vol.31 , pp. 4322-4329
    • Tyne, A.S.1    Chan, J.G.Y.2    Shanahan, E.R.3    Atmosukarto, I.4    Chan, H.-K.5    Britton, W.J.6    West, N.P.7
  • 181
    • 80054935550 scopus 로고    scopus 로고
    • Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections
    • Matinkhoo S., Lynch K.H., Dennis J.J., Finlay W.H., Vehring R. Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections. J. Pharm. Sci. 2011, 100:5197-5205.
    • (2011) J. Pharm. Sci. , vol.100 , pp. 5197-5205
    • Matinkhoo, S.1    Lynch, K.H.2    Dennis, J.J.3    Finlay, W.H.4    Vehring, R.5
  • 182
    • 78650125693 scopus 로고    scopus 로고
    • In vitro lung delivery of bacteriophages KS4-M and ΦKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis
    • Golshahi L., Lynch K.H., Dennis J.J., Finlay W.H. In vitro lung delivery of bacteriophages KS4-M and ΦKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J. Appl. Microbiol. 2011, 110:106-117.
    • (2011) J. Appl. Microbiol. , vol.110 , pp. 106-117
    • Golshahi, L.1    Lynch, K.H.2    Dennis, J.J.3    Finlay, W.H.4
  • 184
    • 0034078730 scopus 로고    scopus 로고
    • Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial
    • Hedrick J.A., Barzilai A., Behre U., Henderson F.W., Hammond J., Reilly L., Keene O. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr. Infect. Dis. J. 2000, 19:410-417.
    • (2000) Pediatr. Infect. Dis. J. , vol.19 , pp. 410-417
    • Hedrick, J.A.1    Barzilai, A.2    Behre, U.3    Henderson, F.W.4    Hammond, J.5    Reilly, L.6    Keene, O.7
  • 185
    • 62849094735 scopus 로고    scopus 로고
    • Cascade impactor practice for a high dose dry powder inhaler at 90L/min: NGI versus modified 6-stage and 8-stage ACI
    • Kamiya A., Sakagami M., Byron P.R. Cascade impactor practice for a high dose dry powder inhaler at 90L/min: NGI versus modified 6-stage and 8-stage ACI. J. Pharm. Sci. 2009, 98:1028-1039.
    • (2009) J. Pharm. Sci. , vol.98 , pp. 1028-1039
    • Kamiya, A.1    Sakagami, M.2    Byron, P.R.3
  • 186
    • 84878413637 scopus 로고    scopus 로고
    • In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults
    • Delvadia R., Hindle M., Worth Longest P., Byron P.R. In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults. J. Aerosol Med. 2013, 26:138-144.
    • (2013) J. Aerosol Med. , vol.26 , pp. 138-144
    • Delvadia, R.1    Hindle, M.2    Worth Longest, P.3    Byron, P.R.4
  • 188
    • 84871361554 scopus 로고    scopus 로고
    • Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics
    • Sunagawa S., Higa F., Cash H.L., Tateyama M., Uno T., Fujita J. Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics. Influenza Other Respi. Viruses 2013, 7:1-3.
    • (2013) Influenza Other Respi. Viruses , vol.7 , pp. 1-3
    • Sunagawa, S.1    Higa, F.2    Cash, H.L.3    Tateyama, M.4    Uno, T.5    Fujita, J.6
  • 189
    • 0035835924 scopus 로고    scopus 로고
    • Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial
    • Diggory P., Fernandez C., Humphrey A., Jones V., Murphy M. Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 2001, 322:577-579.
    • (2001) BMJ , vol.322 , pp. 577-579
    • Diggory, P.1    Fernandez, C.2    Humphrey, A.3    Jones, V.4    Murphy, M.5
  • 191
    • 77953753826 scopus 로고    scopus 로고
    • Fatal respiratory events caused by zanamivir nebulization
    • Steel H.M., Peppercorn A.F. Fatal respiratory events caused by zanamivir nebulization. Clin. Infect. Dis. 2010, 51:121.
    • (2010) Clin. Infect. Dis. , vol.51 , pp. 121
    • Steel, H.M.1    Peppercorn, A.F.2
  • 193
    • 84871361554 scopus 로고    scopus 로고
    • Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics
    • Sunagawa S., Higa F., Cash H.L., Tateyama M., Uno T., Fujita J. Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics. Influenza Other Respir. Viruses 2013, 7:1-3.
    • (2013) Influenza Other Respir. Viruses , vol.7 , pp. 1-3
    • Sunagawa, S.1    Higa, F.2    Cash, H.L.3    Tateyama, M.4    Uno, T.5    Fujita, J.6
  • 194
    • 78751692669 scopus 로고    scopus 로고
    • Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza: a review
    • Yamashita M. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza: a review. Antivir. Chem. Chemother. 2010, 21:71-84.
    • (2010) Antivir. Chem. Chemother. , vol.21 , pp. 71-84
    • Yamashita, M.1
  • 196
    • 84930088282 scopus 로고    scopus 로고
    • Hovione http://www.hovione.com/twincaps/twincaps.asp.
  • 198
    • 59749091876 scopus 로고    scopus 로고
    • CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity
    • Yamashita M., Tomozawa T., Kakuta M., et al. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob. Agents Chemother. 2009, 53:186-192.
    • (2009) Antimicrob. Agents Chemother. , vol.53 , pp. 186-192
    • Yamashita, M.1    Tomozawa, T.2    Kakuta, M.3
  • 199
    • 78649456920 scopus 로고    scopus 로고
    • In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses
    • Kubo S., Kakuta M., Yamashita M. In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses. Jpn. J. Antibiot. 2010, 63:337-346.
    • (2010) Jpn. J. Antibiot. , vol.63 , pp. 337-346
    • Kubo, S.1    Kakuta, M.2    Yamashita, M.3
  • 200
    • 69749088504 scopus 로고    scopus 로고
    • Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation
    • Kawai N., Ikematsu H., Iwaki N., et al. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. J. Infect. 2009, 59:207-212.
    • (2009) J. Infect. , vol.59 , pp. 207-212
    • Kawai, N.1    Ikematsu, H.2    Iwaki, N.3
  • 201
    • 69149093400 scopus 로고    scopus 로고
    • In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses
    • Itoh Y., Shinya K., Kiso M., et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009, 460:1021-1025.
    • (2009) Nature , vol.460 , pp. 1021-1025
    • Itoh, Y.1    Shinya, K.2    Kiso, M.3
  • 202
    • 84930085766 scopus 로고    scopus 로고
    • Biota http://investors.biotapharma.com/releasedetail.cfm?ReleaseID=863626.
  • 204
    • 57749187455 scopus 로고    scopus 로고
    • Developing new antiviral agents for influenza treatment: what does the future hold
    • Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold. Clin. Infect. Dis. 2009, 48:S3-S13.
    • (2009) Clin. Infect. Dis. , vol.48 , pp. S3-S13
    • Hayden, F.1
  • 206
    • 41149168072 scopus 로고    scopus 로고
    • Megaribavirin aerosol for the treatment of influenza A virus infections in mice
    • Gilbert B.E., McLeay M.T. Megaribavirin aerosol for the treatment of influenza A virus infections in mice. Antivir. Res. 2008, 78:223-229.
    • (2008) Antivir. Res. , vol.78 , pp. 223-229
    • Gilbert, B.E.1    McLeay, M.T.2
  • 207
    • 77954175831 scopus 로고    scopus 로고
    • Therapeutic effect of recombinant human catalase on H1N1 influenza-induced pneumonia in mice
    • Shi X.L., Shi Z.H., Huang H., Zhu H.G., Zhou P., Ju D. Therapeutic effect of recombinant human catalase on H1N1 influenza-induced pneumonia in mice. Inflammation 2009, 33:166-172.
    • (2009) Inflammation , vol.33 , pp. 166-172
    • Shi, X.L.1    Shi, Z.H.2    Huang, H.3    Zhu, H.G.4    Zhou, P.5    Ju, D.6
  • 209
    • 80052011287 scopus 로고    scopus 로고
    • Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations
    • Pitman S.K., Drew R.H., Perfect J.R. Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations. Expert Opin. Emerg. Drugs 2011, 16:559-586.
    • (2011) Expert Opin. Emerg. Drugs , vol.16 , pp. 559-586
    • Pitman, S.K.1    Drew, R.H.2    Perfect, J.R.3
  • 210
    • 84864446193 scopus 로고    scopus 로고
    • Pulmonary fungal infections
    • Smith J.A., Kauffman C.A. Pulmonary fungal infections. Respirology 2012, 17:913-926.
    • (2012) Respirology , vol.17 , pp. 913-926
    • Smith, J.A.1    Kauffman, C.A.2
  • 211
    • 74949107171 scopus 로고    scopus 로고
    • Epidemiology of invasive mycoses in North America
    • Pfaller M.A., Diekema D.J. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 2010, 36:1-53.
    • (2010) Crit. Rev. Microbiol. , vol.36 , pp. 1-53
    • Pfaller, M.A.1    Diekema, D.J.2
  • 213
    • 79952186972 scopus 로고    scopus 로고
    • Aerosolised delivery of antifungal agents
    • Le J., Schiller D.S. Aerosolised delivery of antifungal agents. Curr. Fungal Infect. Rep. 2010, 4:96-102.
    • (2010) Curr. Fungal Infect. Rep. , vol.4 , pp. 96-102
    • Le, J.1    Schiller, D.S.2
  • 215
    • 85116178209 scopus 로고    scopus 로고
    • Use of aerosolised antifungals for the prophylaxis against and treatment of invasive pulmonary aspergillosis: climbing it because it is there?
    • Klepser M. Use of aerosolised antifungals for the prophylaxis against and treatment of invasive pulmonary aspergillosis: climbing it because it is there?. Pharm. Anal. Acta 2011, S1:e001.
    • (2011) Pharm. Anal. Acta , vol.S1 , pp. e001
    • Klepser, M.1
  • 216
    • 4143052855 scopus 로고    scopus 로고
    • Development of liposomal amphotericin B dry powder inhaler formulation
    • Shah S.P., Misra A. Development of liposomal amphotericin B dry powder inhaler formulation. Drug Deliv. 2004, 11:247-253.
    • (2004) Drug Deliv. , vol.11 , pp. 247-253
    • Shah, S.P.1    Misra, A.2
  • 217
  • 219
    • 78650061557 scopus 로고    scopus 로고
    • Development of respirable nanomicelle carriers for delivery of amphotericin B by jet nebulisation
    • Gilani K., Moazeni E., Ramezanli T., Amini M., Fazeli M.R., Jamalifar H. Development of respirable nanomicelle carriers for delivery of amphotericin B by jet nebulisation. J. Pharm. Sci. 2011, 100:252-259.
    • (2011) J. Pharm. Sci. , vol.100 , pp. 252-259
    • Gilani, K.1    Moazeni, E.2    Ramezanli, T.3    Amini, M.4    Fazeli, M.R.5    Jamalifar, H.6
  • 221
    • 84871918459 scopus 로고    scopus 로고
    • Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis
    • Rundfeldt C., Steckel H., Scherliess H., Wyska E., Wlaz P. Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis. Eur. J. Pharm. Biopharm. 2013, 83:44-53.
    • (2013) Eur. J. Pharm. Biopharm. , vol.83 , pp. 44-53
    • Rundfeldt, C.1    Steckel, H.2    Scherliess, H.3    Wyska, E.4    Wlaz, P.5
  • 223
    • 79957768993 scopus 로고    scopus 로고
    • Production methods for nanodrug particles using the bottom-up approach
    • Chan H.-K., Kwok P.C.L. Production methods for nanodrug particles using the bottom-up approach. Adv. Drug Deliv. Rev. 2011, 63:406-416.
    • (2011) Adv. Drug Deliv. Rev. , vol.63 , pp. 406-416
    • Chan, H.-K.1    Kwok, P.C.L.2
  • 224
    • 57049163132 scopus 로고    scopus 로고
    • Drug delivery strategies for improved azole antifungal action
    • Yang W., Wiederhold N.P., Williams R.O. Drug delivery strategies for improved azole antifungal action. Expert Opin. Drug Deliv. 2008, 5:1199-1216.
    • (2008) Expert Opin. Drug Deliv. , vol.5 , pp. 1199-1216
    • Yang, W.1    Wiederhold, N.P.2    Williams, R.O.3
  • 225
    • 77951652999 scopus 로고    scopus 로고
    • Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats
    • Yang W., Johnston K.P., Williams R.O. Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Eur. J. Pharm. Biopharm. 2010, 75:33-41.
    • (2010) Eur. J. Pharm. Biopharm. , vol.75 , pp. 33-41
    • Yang, W.1    Johnston, K.P.2    Williams, R.O.3
  • 226
    • 84858748275 scopus 로고    scopus 로고
    • Development of chitosan-based nanoparticles for pulmonary delivery of itraconazole as dry powder formulation
    • Jafarinejad S., Gilani K., Moazeni E., Ghazi-Khansari M., Najafabadi A.R., Mohajel N. Development of chitosan-based nanoparticles for pulmonary delivery of itraconazole as dry powder formulation. Powder Technol. 2012, 222:65-70.
    • (2012) Powder Technol. , vol.222 , pp. 65-70
    • Jafarinejad, S.1    Gilani, K.2    Moazeni, E.3    Ghazi-Khansari, M.4    Najafabadi, A.R.5    Mohajel, N.6
  • 227
    • 84870316205 scopus 로고    scopus 로고
    • New inhalation-optimised itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis
    • Duret C., Wauthoz N., Sebti T., Vanderbist F., Amighi K. New inhalation-optimised itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis. Int. J. Nanomedicine 2012, 7:5475-5489.
    • (2012) Int. J. Nanomedicine , vol.7 , pp. 5475-5489
    • Duret, C.1    Wauthoz, N.2    Sebti, T.3    Vanderbist, F.4    Amighi, K.5
  • 228
    • 84896738432 scopus 로고    scopus 로고
    • Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention
    • Duret C., Merlos R., Wauthoz N., Sebti T., Vanderbist F., Amighi K. Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. Eur. J. Pharm. Biopharm. 2014, 86:46-54.
    • (2014) Eur. J. Pharm. Biopharm. , vol.86 , pp. 46-54
    • Duret, C.1    Merlos, R.2    Wauthoz, N.3    Sebti, T.4    Vanderbist, F.5    Amighi, K.6
  • 229
    • 84862832377 scopus 로고    scopus 로고
    • Effect of process variables on morphology and aerodynamic properties of voriconazole formulations produced by thin film freezing
    • Beinborn N.A., Lirola H.L., Williams R.O. Effect of process variables on morphology and aerodynamic properties of voriconazole formulations produced by thin film freezing. Int. J. Pharm. 2012, 429:46-57.
    • (2012) Int. J. Pharm. , vol.429 , pp. 46-57
    • Beinborn, N.A.1    Lirola, H.L.2    Williams, R.O.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.